Gene therapy for longevity targets the genetic and molecular pathways known to influence how fast an organism ages: telomere maintenance (the protective caps on chromosomes that shorten with cell division), DNA repair mechanisms, and nutrient-sensing pathways like mTOR signaling that link diet, metabolism, and aging rate across species. Unlike cellular reprogramming, which resets a cell's overall epigenetic state, gene therapy approaches tend to target one specific pathway at a time, adding, editing, or modulating expression of particular genes.
George Church's lab has pursued some of the most ambitious combinatorial gene therapy approaches to aging, while Brian Kennedy's research has focused heavily on the mTOR and nutrient-sensing pathways that are among the best-validated aging-rate regulators across model organisms from yeast to mice. The field also has a notable, widely reported case of self-experimentation, a biotech executive administering an experimental telomerase gene therapy to herself, which generated public attention but does not constitute the kind of controlled clinical evidence needed to establish safety or efficacy for broader use.
Of the four therapy classes tracked here, gene therapy for general longevity is the earliest-stage and most indication-specific: individual gene therapies have real clinical validation for specific rare diseases, but no gene therapy protocol for slowing aging broadly has cleared human trials. Readers should treat any current longevity gene therapy claim as investigational.